Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Large Increase in Short Interest

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 17,195 shares, a growth of 113.0% from the December 15th total of 8,073 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 42,362 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 42,362 shares, the short-interest ratio is currently 0.4 days. Currently, 1.0% of the shares of the stock are short sold.

Catheter Precision Trading Down 5.8%

Shares of Catheter Precision stock traded down $0.13 during trading hours on Friday, reaching $2.13. 18,979 shares of the company’s stock were exchanged, compared to its average volume of 20,369. The business has a fifty day moving average of $2.08 and a two-hundred day moving average of $2.74. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.46 and a quick ratio of 0.46. Catheter Precision has a 1 year low of $1.49 and a 1 year high of $15.68.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($1.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($26.60) by $24.90. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $1.20 million. Catheter Precision had a negative net margin of 2,333.29% and a negative return on equity of 208.54%. Equities research analysts predict that Catheter Precision will post -8.9 EPS for the current fiscal year.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.